82071-04-3Relevant academic research and scientific papers
Diaryl-containing imidazole compound and preparation method and medical application thereof
-
Paragraph 0147; 0152; 0153, (2019/02/21)
The invention discloses a diaryl-containing imidazole compound. The invention further discloses application of the diaryl-containing imidazole compound to preparation of drugs for preventing or treating Alzheimer's disease. The inventor screens butyrylcholine esterase and IDO1 as carriers for inhibiting the activity to evaluate the effect of the diaryl imidazole compound to treat Alzheimer's disease, and finds that the diaryl imidazole compound has good in vitro activity, and can be further developed as a precursor substance for performing the Alzheimer's disease resistant effect by inhibitingthe activity of cholinesterase. (The formula is shown in the description).
Synthesis and antifungal activity of phenacyl azoles
Nelson, Ronald,Kesternich, Vctor,Perz-Fehrmann, Marcia,Salazar, Fernanda,Marcourt, Laurence,Christen, Philippe,Godoy, Patricio
, p. 549 - 552 (2014/12/11)
A new N-(4-methoxyphenacyl)imidazole and three new substituted N-(phenacyl)triazoles were prepared by reaction of the heterocycle with a phenacyl halide. The former ketone and one example of the latter were reduced to the corresponding alcohols. All six compounds were screened in vitro for antifungal activity against two pathogenic fungal strains, Candida albicans (fluconazole-resistant) and Aspergillus fumigatus. The results revealed that most of the compounds showed activity against both strains at 100 μg mL-1and 80 μg mL-1, some comparable with control compound fluconazole. The alcohols were less active than the corresponding ketones.
Synthesis and anticonvulsant activity of N-(benzoylalkyl)imidazoles and N-(ω-phenyl-ω-hydroxyalkyl)imidazoles
Nardi,Tajana,Leonardi,Pennini,Portioli,Magistretti,Subissi
, p. 727 - 731 (2007/10/02)
A novel series of N-(benzoylalkyl)imidazoles and N-(ω-phenyl-ω-hydroxyalkyl)imidazoles was synthesized and evaluated for anticonvulsant activity in mice against maximal electroshock induced seizures. Some of the compounds showed an activity comparable to or better than phenytoin and phenobarbital. The N-[β-[4-(β-phenylethyl)phenyl]-β-hydroxyethyl]imidazole (38) was selected for further studies; preclinical toxicology and additional efficacy evaluations are in progress. Structure-activity relationships are discussed.
